Barclays
STRO icon

Barclays’s Sutro Biopharma STRO Stock Holding History

Barclays’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.46K Buy
+139
New +$2.51K ﹤0.01% 4807
2025
Q4 		– Sell
-277
Closed -$2.4K – 5665
2025
Q3 		$2.4K Sell
277
-385
-58% -$3.28K ﹤0.01% 5135
2025
Q2 		$4.72K Sell
662
-10,967
-94% -$89.7K ﹤0.01% 4981
2025
Q1 		$75.7K Sell
11,629
-4,252
-27% -$67K ﹤0.01% 4491
2024
Q4 		$292K Sell
15,881
-11,421
-42% -$349K ﹤0.01% 4131
2024
Q3 		$945K Buy
27,302
+21,676
+385% +$850K ﹤0.01% 3390
2024
Q2 		$165K Sell
5,626
-2,348
-29% -$92.8K ﹤0.01% 3677
2024
Q1 		$451K Sell
7,974
-5,232
-40% -$231K ﹤0.01% 3659
2023
Q4 		$567K Buy
13,206
+6,948
+111% +$220K ﹤0.01% 3803
2023
Q3 		$217K Buy
6,258
+1,809
+41% +$78.8K ﹤0.01% 3255
2023
Q2 		$207K Sell
4,449
-7,665
-63% -$382K ﹤0.01% 3221
2023
Q1 		$560K Buy
12,114
+3,924
+48% +$249K ﹤0.01% 3184
2022
Q4 		$662K Buy
8,190
+6,147
+301% +$427K ﹤0.01% 3117
2022
Q3 		$114K Sell
2,043
-341
-14% -$20.2K ﹤0.01% 3489
2022
Q2 		$125K Sell
2,384
-2,975
-56% -$166K ﹤0.01% 3677
2022
Q1 		$441K Sell
5,359
-30,080
-85% -$2.86M ﹤0.01% 2988
2021
Q4 		$5.27M Buy
35,439
+2,377
+7% +$426K ﹤0.01% 1674
2021
Q3 		$6.25M Buy
33,062
+9,163
+38% +$1.74M ﹤0.01% 1479
2021
Q2 		$4.44M Sell
23,899
-2,113
-8% -$414K ﹤0.01% 1665
2021
Q1 		$5.92M Buy
26,012
+3,000
+13% +$712K ﹤0.01% 1388
2020
Q4 		$5M Sell
23,012
-901
-4% -$149K ﹤0.01% 1528
2020
Q3 		$2.4M Buy
23,913
+177
+0.7% +$16.7K ﹤0.01% 1942
2020
Q2 		$1.84M Buy
23,736
+742
+3% +$71.2K ﹤0.01% 2202
2020
Q1 		$2.35M Buy
22,994
+21,164
+1,157% +$2.22M ﹤0.01% 2152
2019
Q4 		$202K Buy
1,830
+557
+44% +$57.4K ﹤0.01% 5021
2019
Q3 		$116K Buy
1,273
+300
+31% +$30.3K ﹤0.01% 5369
2019
Q2 		$111K Buy
973
+792
+438% +$87.3K ﹤0.01% 5603
2019
Q1 		$21K Buy
181
+81
+81% +$8.43K ﹤0.01% 6347
2018
Q4 		$9K Buy
+100
New +$12.1K ﹤0.01% 6228

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Barclays's STRO Position: Q1 2026 in Review

Barclays opened a new position in Sutro Biopharma (STRO) in Q1 2026: 139 shares worth $3.46K. The stake represents ﹤0.01% of the portfolio and ranks #4807 among its holdings. This is a return to the name: Barclays previously reported a position in STRO as recently as Q3 2025.

Barclays first reported a position in STRO in Q4 2018 and has held it in 29 quarters since. The position peaked at $6.25M in Q3 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Barclays held 139 shares of Sutro Biopharma worth $3.46K as of Q1 2026.
  • Sutro Biopharma was a new Barclays position in Q1 2026.
  • Sutro Biopharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4807 holding.
  • Barclays first reported a position in Sutro Biopharma in Q4 2018 and has held it in 29 quarters since.
  • Barclays's Sutro Biopharma position peaked at $6.25M in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.